BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26502886)

  • 1. Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.
    Ge S; Yin T; Xu B; Gao S; Hu M
    Pharm Res; 2016 Mar; 33(3):590-602. PubMed ID: 26502886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and use of new MDCK II cells overexpressing both UGT1A1 and MRP2 to characterize flavonoid metabolism via the glucuronidation pathway.
    Wang M; Yang G; He Y; Xu B; Zeng M; Ge S; Yin T; Gao S; Hu M
    Mol Nutr Food Res; 2016 Sep; 60(9):1967-83. PubMed ID: 26833852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
    Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
    Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
    Xiao L; Yi T; Chen M; Lam CW; Zhou H
    Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP.
    Jiang W; Xu B; Wu B; Yu R; Hu M
    Drug Metab Dispos; 2012 Feb; 40(2):336-45. PubMed ID: 22071170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport-Glucuronidation Classification System and PBPK Modeling: New Approach To Predict the Impact of Transporters on Disposition of Glucuronides.
    Ge S; Wei Y; Yin T; Xu B; Gao S; Hu M
    Mol Pharm; 2017 Sep; 14(9):2884-2898. PubMed ID: 28221813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efflux excretion of bisdemethoxycurcumin-O-glucuronide in UGT1A1-overexpressing HeLa cells: Identification of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins 1 (MRP1) as the glucuronide transporters.
    Yang J; Zhang B; Qin Z; Li S; Xu J; Yao Z; Zhang X; Gonzalez FJ; Yao X
    Biofactors; 2018 Nov; 44(6):558-569. PubMed ID: 30334318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
    Wortelboer HM; Usta M; van der Velde AE; Boersma MG; Spenkelink B; van Zanden JJ; Rietjens IM; van Bladeren PJ; Cnubben NH
    Chem Res Toxicol; 2003 Dec; 16(12):1642-51. PubMed ID: 14680379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
    J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
    Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
    Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of the glucuronide and sulfate conjugates of genistein and daidzein in breast cancer resistance protein 1 knockout mice.
    Álvarez AI; Vallejo F; Barrera B; Merino G; Prieto JG; Tomás-Barberán F; Espín JC
    Drug Metab Dispos; 2011 Nov; 39(11):2008-12. PubMed ID: 21828252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
    Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
    Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
    Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
    Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
    Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of chrysin glucuronidation in UGT1A1-overexpressing HeLa cells: elucidating the transporters responsible for efflux of glucuronide.
    Quan E; Wang H; Dong D; Zhang X; Wu B
    Drug Metab Dispos; 2015 Apr; 43(4):433-43. PubMed ID: 25595598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.